Subjects

Abstract

Purpose

Whole-exome sequencing (WES) has revolutionized Mendelian diagnostics, however, there is no consensus on the timing of data review in undiagnosed individuals and only preliminary data on the cost-effectiveness of this technology. We aimed to assess the utility of WES data reanalysis for diagnosis in Mendelian disorders and to analyze the cost-effectiveness of this technology compared with a traditional diagnostic pathway.

Methods

WES was applied to a cohort of 54 patients from 37 families with a variety of Mendelian disorders to identify the genetic etiology. Reanalysis was performed after 12 months with an improved WES diagnostic pipeline. A comparison was made between costs of a modeled WES pathway and a traditional diagnostic pathway in a cohort with intellectual disability (ID).

Results

Reanalysis of WES data at 12 months improved diagnostic success from 30 to 41% due to interim publication of disease genes, expanded phenotype data from referrer, and an improved bioinformatics pipeline. Cost analysis on the ID cohort showed average cost savings of US$586 (AU$782) for each additional diagnosis.

Conclusion

Early application of WES in Mendelian disorders is cost-effective and reanalysis of an undiagnosed individual at a 12-month time point increases total diagnoses by 11%.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    World Health Organization. Genes and human disease. http://www.who.int/genomics/public/geneticdiseases/en/index2.html. Accessed 22 March 2015.

  2. 2

    Central Intelligence Agency. The World Factbook. 2016. https://www.cia.gov/library/publications/the-world-factbook/geos/xx.html; Accessed 22 March 2018.

  3. 3

    Rabbani B, Tekin M & Mahdieh N. The promise of whole-exome sequencing in medical genetics. J Hum Genet 2014;59:5–15.

  4. 4

    Shashi V, McConkie-Rosell A, Rosell B et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. Genet Med 2014;16:176–182.

  5. 5

    Bamshad MJ, Ng SB, Bigham AW et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011;12:745–755.

  6. 6

    Gilissen C, Hoischen A, Brunner HG & Veltman JA. Unlocking Mendelian disease using exome sequencing. Genome 2011;11:64.

  7. 7

    Rabbani B, Mahdieh N, Hosomichi K, Nakaoka H & Inoue I. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet 2012;57:621–632.

  8. 8

    Zhang X. Exome sequencing greatly expedites the progressive research of Mendelian diseases. Front Med 2014;8:42–57.

  9. 9

    Jacob H, Abrams K, Bick D et al. Genomics in clinical practice: lessons from the front lines. Sci Transl Med 2013;5:194cm5.

  10. 10

    Biesecker LG & Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med 2014;370:2418–2425.

  11. 11

    Wenger AM, Guturu H, Bernstein JA & Bejerano G. Systematic reanalysis of clinical exome data yields additional diagnoses: implications for providers. Genet Med 2017;19:209–214.

  12. 12

    Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM & Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46:310–315.

  13. 13

    Paila U, Chapman BA, Kirchner R & Quinlan AR. GEMINI: integrative exploration of genetic variation and genome annotations. PLoS Comput Biol 2013;9:e1003153.

  14. 14

    Choi Y & Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics 2015;31:2745–2747.

  15. 15

    Seelow D, Schuelke M, Hildebrandt F & Nurnberg P. Homozygosity Mapper—an interactive approach to homozygosity mapping. Nucleic Acids Res 2009;37:W593–W599.

  16. 16

    Thorvaldsdottir H, Robinson JT & Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178–192.

  17. 17

    Richards S, Aziz N, Bale S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–423.

  18. 18

    NSW Health. NSW Health Renumerations and Conditions. NSW Government Health. 2016. http://www.health.nsw.gov.au/careers/conditions/Pages/default.aspx; Accessed 22 March 2018.

  19. 19

    Australian Government Department of Health. Medicare Benefits Schedule Book. April 2014. http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home; Accessed 22 March 2018.

  20. 20

    Denayer E, Parret A, Chmara M et al. Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation. Hum Mutat 2008;29:232–239.

  21. 21

    Loveday C, Tatton-Brown K, Clarke M et al. Mutations in the PP2A regulatory subunit B family genes PPP2R5B PPP2R5C and PPP2R5D cause human overgrowth. Hum Mol Genet 2015;24:4775–4779.

  22. 22

    Kremer LS, Distelmaier F, Alhaddad B et al. Bi-allelic truncating mutations in TANGO2 cause infancy-onset recurrent metabolic crises with encephalocardiomyopathy. Am J Hum Genet 2016;98:358–362.

  23. 23

    Lalani SR, Liu P, Rosenfeld JA et al. Recurrent muscle weakness with rhabdomyolysis, metabolic crises, and cardiac arrhythmia due to bi-allelic TANGO2 mutations. Am J Hum Genet 2016;98:347–357.

  24. 24

    Gilissen C, Hehir-Kwa JY, Thung DT et al. Genome sequencing identifies major causes of severe intellectual disability. Nature 2014;511:344–347.

  25. 25

    Soden SE, Saunders CJ, Willig LK et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med 2014;6:265ra168.

  26. 26

    Yang Y, Muzny DM, Reid JG et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N Engl J Med 2013;369:1502–1511.

  27. 27

    Farwell KD, Shahmirzadi L, El-Khechen D et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med 2015;17:578–586.

  28. 28

    Lazaridis KN, Schahl KA, Cousin MA et al. Outcome of whole exome sequencing for diagnostic odyssey cases of an individualized medicine clinic. Mayo Clin Proc 2016;91:297–307.

  29. 29

    Retterer K, Juusola J, Cho MT et al. Clinical application of whole-exome sequencing across clinical indications. Genet Med 2016;18:696–704.

  30. 30

    Kassahn KS, Scott HS & Caramins MC. Integrating massively parallel sequencing into diagnostic workflows and managing the annotation and clinical interpretation challenge. Hum Mutat 2014;35:413–423.

  31. 31

    Lee H, Deignan JL, Dorrani N et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014;312:1880.

  32. 32

    Choi M, Scholl UI, Ji W et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 2009;106:19096–19101.

  33. 33

    Majewski J, Wang Z, Lopez I et al. A new ocular phenotype associated with an unexpected but known systemic disorder and mutation: novel use of genomic diagnostics and exome sequencing. J Med Genet 2011;48:593–596.

  34. 34

    Zhan Z, Liao X, Du J et al. Exome sequencing released a case of X-linked adrenoleukodystrophy mimicking recessive hereditary spastic paraplegia. Eur J Med Genet 2013;56:375–378.

  35. 35

    Sawyer SL, Hartley T, Dyment DA et al. Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care: whole-exome sequencing for rare disease diagnosis. Clin Genet 2016;89:275–284.

  36. 36

    Kleefstra T, Wortmann S, Rodenburg R et al. Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway. Eur J Hum Genet 2011;19:138–144.

  37. 37

    Stark Z, Schofield D, Alam K et al. Prospective comparison of the cost-effectiveness of clinical whole-exome sequencing with that of usual care overwhelmingly supports early use and reimbursement. Genet Med 2017;19:867–874.

  38. 38

    Doran CM, Einfeld SL, Madden RH et al. How much does intellectual disability really cost? First estimates for Australia. J Intellect Dev Disabil 2012;37:42–49.

  39. 39

    Belkadi A, Bolze A, Itan Y et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA 2015;112:5473–5478.

  40. 40

    Eldomery MK, Coban-Akdemir Z, Harel T et al. Lessons learned from additional research analyses of unsolved clinical exome cases. Genome Med 2017;9:26.

Download references

Acknowledgments

Whole-exome sequencing was funded through a donation by the Kinghorn Foundation to the Garvan Institute of Medical Research. L.J.E. is supported through an Australian Government Research Training Program Scholarship. M.J.C. is supported by Cancer Institute NSW (13/ECF/1-46). T.R. was supported by the Australian National Health and Medical Research Council (APP1117394 Transforming the Diagnosis and Management of Severe Neurocognitive Disorders through Genomics; APP1045465 Gene Identification in Familial Orofacial Clefts by Next Generation Sequencing of Exomes and p63 regulatory elements and an International Biomedical Fellowship 512123 Identification of genes for intellectual disability and brain malformations). We thank the patients, their families, and physicians for their participation in this study. We also thank Jiang Tao, Paula Morris, and Kerith-Rae Dias from the Kinghorn Centre for Clinical Genomics for sequencing these patients.

Author information

Affiliations

  1. St Vincent’s Clinical School, University of New South Wales, Darlinghurst, New South Wales, Australia

    • Lisa J Ewans MBBS, BSc
    • , Marcel E Dinger PhD
    •  & Mark J Cowley BSc, PhD
  2. Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia

    • Lisa J Ewans MBBS, BSc
    • , Deborah Schofield BSpPath, PhD
    • , Velimir Gayevskiy MSc, PhD
    • , Kevin Ying BSc, MBiomedE
    • , David Miller BAppSc
    • , Marcel E Dinger PhD
    •  & Mark J Cowley BSc, PhD
  3. Faculty of Pharmacy, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia

    • Deborah Schofield BSpPath, PhD
    •  & Rupendra Shrestha MSc, PhD
  4. Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, Victoria, Australia

    • Deborah Schofield BSpPath, PhD
  5. The Genetics of Learning Disability Service, Waratah, New South Wales, Australia

    • Ying Zhu PhD
    •  & Michael Field MBChB, MPhil
  6. Randwick Genetics, NSW Health Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia

    • Ying Zhu PhD
    • , Corrina Walsh BSc, MHGSA
    • , Eric Lee MBBS, FRCPA
    • , Edwin P Kirk MBBS, PhD
    • , Michael F Buckley MBChB, FRCPA
    •  & Tony Roscioli FRACP, FRCPath
  7. Centre for Clinical Genetics, Sydney Children’s Hospital, Randwick, New South Wales, Australia

    • Edwin P Kirk MBBS, PhD
    • , Carolyn Ellaway MBBS, PhD
    • , Anne Turner MBBS, FRACP
    • , David Mowat MBBS, FRACP
    • , Mary-Louise Freckmann BMed, FRACP
    • , Michelle Lipke MBBS, FRACP
    • , Rani Sachdev MBBS, FRACP
    •  & Tony Roscioli FRACP, FRCPath
  8. School of Women’s and Children’s Health, University of New South Wales, Sydney, New South Wales, Australia

    • Edwin P Kirk MBBS, PhD
    • , Anne Turner MBBS, FRACP
    • , David Mowat MBBS, FRACP
    • , Mary-Louise Freckmann BMed, FRACP
    •  & Rani Sachdev MBBS, FRACP
  9. Clinical Genetics Department, Liverpool Hospital, Liverpool, New South Wales, Australia

    • Alison Colley MBBS, MMedSc
    •  & Lisa Worgan MBBS, MSc
  10. Disciplines of Child and Adolescent Health and Genetic Medicine, University of Sydney, New South Wales, Australia

    • Carolyn Ellaway MBBS, PhD
  11. Lady Cilento Children’s Hospital, Brisbane, Queensland, Australia

    • Michelle Lipke MBBS, FRACP
  12. NeuRA and Prince of Wales Clinical School, University of New South Wales, Kensington, Australia, New South Wales

    • Tony Roscioli FRACP, FRCPath

Authors

  1. Search for Lisa J Ewans MBBS, BSc in:

  2. Search for Deborah Schofield BSpPath, PhD in:

  3. Search for Rupendra Shrestha MSc, PhD in:

  4. Search for Ying Zhu PhD in:

  5. Search for Velimir Gayevskiy MSc, PhD in:

  6. Search for Kevin Ying BSc, MBiomedE in:

  7. Search for Corrina Walsh BSc, MHGSA in:

  8. Search for Eric Lee MBBS, FRCPA in:

  9. Search for Edwin P Kirk MBBS, PhD in:

  10. Search for Alison Colley MBBS, MMedSc in:

  11. Search for Carolyn Ellaway MBBS, PhD in:

  12. Search for Anne Turner MBBS, FRACP in:

  13. Search for David Mowat MBBS, FRACP in:

  14. Search for Lisa Worgan MBBS, MSc in:

  15. Search for Mary-Louise Freckmann BMed, FRACP in:

  16. Search for Michelle Lipke MBBS, FRACP in:

  17. Search for Rani Sachdev MBBS, FRACP in:

  18. Search for David Miller BAppSc in:

  19. Search for Michael Field MBChB, MPhil in:

  20. Search for Marcel E Dinger PhD in:

  21. Search for Michael F Buckley MBChB, FRCPA in:

  22. Search for Mark J Cowley BSc, PhD in:

  23. Search for Tony Roscioli FRACP, FRCPath in:

Disclosure

L.J.E. and M.E.D. are employees of Genome.One, a whole-owned subsidiary of the Garvan Institute for Medical Research. M.F.B., E.P.K, E.L., and C.W. are employees of Randwick Genetics, NSW Health Pathology East. The other authors declare no conflict of interest.

Corresponding author

Correspondence to Lisa J Ewans MBBS, BSc.

Electronic supplementary material

About this article

Publication history

Received

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/gim.2018.39

Further reading